Relationship between disease stage and renal function in bisphosphonate-related osteonecrosis of the jaw

키워드

참고문헌 (37)

1. Coleman RE, "Optimising treatment of bone metastases by Aredia(TM) and Zometa(TM)", Breast Cancer, 7, pp.361~369 (2000)
2. Berenson JR, "American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma", J Clin Oncol, 20, pp.3719~3736 (2002)
3. Bone HG, "Ten years' experience with alendronate for osteoporosis in postmenopausal women", N Engl J Med, 350, pp.1189~1199 (2004)
4. Park HM, "The use of osteoporosis medications in Korea in 2008", Korean J Bone Metab, 16, pp.87~93 (2009)
5. Miller PD, "The kidney and bisphosphonates", Bone, 49, pp.77~81 (2011)
6. Lin JH, "Bisphosphonates: a review of their pharmacokinetic properties", Bone, 18, pp.75~85 (1996)
7. "Wikipedia: Renal function" (2017)[URL]
8. Marx RE, "Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic", J Oral Maxillofac Surg, 61, pp.1115~1117 (2003)
9. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws:2009 update", J Oral Maxillofac Surg, 67(5 Suppl), pp.2~12 (2009)
10. Silva PG, "Effect of different doses of zoledronic acid in establishing of bisphosphonate-related osteonecrosis", Arch Oral Biol, 60, pp.1237~1245 (2015)
11. Manzano-Moreno FJ, "High doses of bisphosphonates reduce osteoblast-like cell proliferation by arresting the cell cycle and inducing apoptosis", J Craniomaxillofac Surg, 43, pp.396~401 (2015)
12. National Kidney Foundation, "K", DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification, 2002, pp.39(2 Suppl 1), S1~S266
13. Levey AS, "Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)", Kidney Int, 67, pp.2089~2100 (2005)
14. Levey AS, "A new equation to estimate glomerular filtration rate", Ann Intern Med, 150, pp.604~612 (2009)
15. Park JC, "The effectiveness of the surgical approach and drug-holiday on the treatment of bisphosphonate related osteonecrosis of the jaw patient", Int J Oral Maxillofac Surg, 44(Suppl 1), pp.e275~ (2015)
16. Nickolas TL, "Chronic kidney disease and bone fracture: a growing concern", Kidney Int, 74, pp.721~731 (2008)
17. Coresh J, "Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey", Am J Kidney Dis, 41, pp.1~12 (2003)
18. Khosla S, "Bisphosphonate-associated osteonecrosis of the jaw:report of a task force of the American Society for Bone and Mineral Research", J Bone Miner Res, 22, pp.1479~1491 (2007)
19. Ruggiero SL, "American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw: 2014 update", J Oral Maxillofac Surg, 72, pp.1938~1956 (2014)
20. O'Hare AM, "Age affects outcomes in chronic kidney disease", J Am Soc Nephrol, 18, pp.2758~2765 (2007)
21. Gifre L, "Effect of bisphosphonates on renal function in patients with osteoporosis", Eur Geriatr Med, 4, pp.380~383 (2013)
22. 이정근, "Bisphosphonates-related osteonecrosis of the jaw in Korea: a preliminary report", 대한구강악안면외과학회지, 39(1), pp.9~13 (2013), 대한구강악안면외과학회
23. "Background document for meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee" (2011)[URL]
24. Mavrokokki T, "Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia", J Oral Maxillofac Surg, 65, pp.415~423 (2007)
25. Damm DD, "Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays", Gen Dent, 61, pp.33~38 (2013)
26. Marx RE, "Oral bisphosphonate-induced osteonecrosis:risk factors, prediction of risk using serum CTX testing, prevention, and treatment", J Oral Maxillofac Surg, 65, pp.2397~2410 (2007)
27. 송진우, "비스포스포네이트 관련 악골괴사환자의 혈청 C-terminal cross linking telopeptide 수치에 따른 위험도 평가와 질환의 심도 및 조기 수술 후 치유 사이의 상관관계", 대한구강악안면외과학회지, 37(1), pp.1~8 (2011), 대한구강악안면외과학회
28. Grbic JT, "The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program", J Am Dent Assoc, 141, pp.1365~1370 (2010)
29. Park W, "Osteonecrosis of the jaw induced by oral administration of bisphosphonates in Asian population: five cases", Osteoporos Int, 21, pp.527~533 (2010)
30. Bamias A, "Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors", J Clin Oncol, 23, pp.8580~8587 (2005)
31. Hoff A, "Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy", J Clin Oncol, 24, pp.8528~ (2006)
32. Baqain ZH, "Osteonecrosis of jaws related to intravenous bisphosphonates:the experience of a Jordanian teaching hospital", Ann R Coll Surg Engl, 92, pp.489~494 (2010)
33. Vahtsevanos K, "Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw", J Clin Oncol, 27, pp.5356~5362 (2009)
34. Markowitz GS, "Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate", J Am Soc Nephrol, 12, pp.1164~1172 (2001)
35. Markowitz GS, "Toxic acute tubular necrosis following treatment with zoledronate (Zometa)", Kidney Int, 64, pp.281~289 (2003)
36. Suresh E, "Safety issues with bisphosphonate therapy for osteoporosis", Rheumatology, 53, pp.19~31 (2014)
37. Levey AS, "National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification", Ann Intern Med, 139, pp.137~147 (2003)

관련 논문AI추천